Skip to content

A Feasibility Trial and Protocol for Remote Cognitive Training Developed for Use in a Cognitively Healthy Adult Population During the COVID-19 Pandemic

A Feasibility Trial and Protocol for Remote Cognitive Training Developed for Use in a Cognitively Healthy Adult Population During the COVID-19 Pandemic

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05278273
Enrollment
20
Registered
2022-03-14
Start date
2021-01-04
Completion date
2022-03-10
Last updated
2022-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognition Disorders in Old Age

Keywords

3-dimensional multiple object tracking, Cognitive Training, Neurotracker

Brief summary

The COVID-19 pandemic has created a shift in the use of at-home spaces for work, play and research. In the current study, the feasibility of implementing an at-home cognitive training tool called NeuroTrackerX, an anaglyph version of the three-dimensional multiple object tracking (3D-MOT) software NeuroTracker was examined, and with the intent of developing an effective protocol and determining the suitability of this tool for research purposes .

Detailed description

The work looks at the feasibility of using a newly developed anaglyph 3D cognitive training tool called NeuroTrackerX in research with adult participants. The work looks to validate an at-home program by comparing participants who complete an online version of Neurotracker (NeurotrackerX) with a group of individuals who completed the classically used in-lab version (Neurotracker). Due to COVID-19, many laboratories forced to transition to remote-based studies, and the purpose of the work is to validate the remote-based protocol. Twenty cognitively healthy adults (10 Male; 10 female) were recruited to engage in this at-home program. The results of these individuals will be compared with results from a group of cognitively healthy adults who had previously engaged in the in-lab version of the program prior to the pandemic.

Interventions

DEVICENeurotrackerX

At-home participants loaned the necessary equipment (e.g., 3D-glasses, computer equipment) from the research facilities and engaged in 10 training sessions over five weeks (2x per week). Participant recruitment, retention, adherence and experience were used as markers of feasibility. For program validation, twenty participants above 50 years old, who had previously completed at least eight sessions of the in-lab 3D-MOT program, were randomly selected as the control group.

Sponsors

University of Victoria
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Intervention model description

Twenty adults (10 female, 10 male) will serve as the at-home training group. The cognitive health status for participants will be assessed using a self-report questionnaire and the Mini-Mental State Examination (MMSE), and all participants were deemed cognitively healthy (MMSE \> 26). At-home participants loaned the necessary equipment (e.g., 3D-glasses, computer equipment) from the research facilities and engaged in 10 training sessions over five weeks (2x per week). Participant recruitment, retention, adherence and experience will be used as markers of feasibility. For program validation, twenty participants above 50 years old, who had previously completed at least eight sessions of the in-lab 3D-MOT program, were randomly selected as the control group. Individual session scores, overall improvement and learning rates between groups will be compared.

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Inclusion criteria for both groups included being aged 50 years and older and to have either normal or corrected vision.

Exclusion criteria

*

Design outcomes

Primary

MeasureTime frameDescription
Neurotracker scores5 weeksPerformance on the multiple-object tracking program across 10 sessions. Scores are between 0 - 4, with increasing scores indicating increasing performance.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026